A 59-year-old man with relapsed epidermal growth factor receptor (<i>EGFR</i>) exon 19 deletion-positive stage IA adenosquamous carcinoma after lobectomy was treated with erlotinib and bevacizumab for 1 year followed by erlotinib alone for 1 year. The gene discussed is EGFR; the disease is adenosquamous carcinoma.